Meeting Minutes: Drug Formulary Committee

Date & Time: December 11, 2018; 5:30-9 PM
Minutes prepared by: Hind Douiki and Dave Hoang
Location: Elmer Andersen Building, Room 2370, 540 Cedar Street, St. Paul, MN 55101

Attendance

• DHS staff present: Jeff Schiff, M.D., MBA; Chad Hope, Pharm.D.; Dave Hoang, Pharm.D., MBA; Mary Beth Reinke, Pharm.D., MSA.; Teagen Warrick (pharmacy student)
• Others in attendance: Hind Douiki, Pharm.D.; Ariane Casey, Pharm.D.

Report of the Chair

No report

Approval of Minutes

Minutes from the October 2018 meeting were reviewed and approved.

DHS Housekeeping

• Chad Hope informed the committee that doxylamine coverage implementation is still pending and that DHS is currently in the process of determining rebate-eligible manufacturers.
• Chad Hope informed the committee that Rx Polyethylene Glycol (PEG) is no longer available. The committee recommended to the department by a unanimous vote to recommend coverage of OTC PEG.
• Chad Hope and Dave Hoang informed the committee that the February 2019 DFC meeting will be entirely regarding the uniform PDL. They also requested that the meeting scope be kept strictly clinical and indicated that larger PDL classes will be reviewed first.
• Dave Hoang and Ariane Casey provided a presentation to the committee outlining behind-the-scene information regarding the prior authorization (PA) process and how PA requests are reviewed.
Old Business

New Specialty Drugs for Continued PA

- The committee discussed Probuphine and recommended to the department by a unanimous vote that Probuphine remain on PA.

New Business

New Specialty Drugs for Continued PA

- The committee discussed Sublocade and recommended to the department by a unanimous vote that Sublocade remain on PA.

- The committee discussed Aimovig and recommended to the department by a unanimous vote that Aimovig remain on PA, with the following revisions to the criteria:
  1. The addition of the following criterion: “Patient must be at least 18 years of age”
  2. Changing the third bullet language to the following: “Medication overuse headache has been considered”

- The committee discussed Ajovy and recommended to the department by a unanimous vote that Ajovy remain on PA, with the following revisions to the criteria:
  1. The addition of the following criterion: “Patient must be at least 18 years of age”
  2. Changing the third bullet language to the following: “Medication overuse headache has been considered”

- The committee discussed Emgality and recommended to the department by a unanimous vote that Emgality remain on PA, with the following revisions to the criteria:
  3. The addition of the following criterion: “Patient must be at least 18 years of age”
  4. Changing the third bullet language to the following: “Medication overuse headache has been considered”

- The committee discussed Lutathera and recommended to the department by a unanimous vote that Lutathera remain on PA, with the modification of the first criterion language to “females with childbearing potential”

- The committee discussed Sinuva and recommended to the department by a unanimous vote that Sinuva remain on PA, with the modification of the third bullet language to the following: “Patient has nasal obstruction/congestion score of ≥ 2 despite use of 2 preferred intranasal corticosteroids”

- The committee discussed Xhance and recommended to the department by a unanimous vote that Xhance remain on PA.

- The committee discussed Lucemyra and recommended to the department by a unanimous vote that Lucemyra remain on PA, with the addition of the following criterion: “Patient has diagnosis of opioid withdrawal symptoms”
The committee discussed Yonsa and recommended to the department by a unanimous vote that Yonsa remain on PA.

The committee discussed Palynziq and recommended to the department by a unanimous vote that Palynziq remain on PA, with addition of the following criteria:

1. An epinephrine auto-injector must be prescribed to the patient
2. Covered medical food for low-phenylalanine diet must be prescribed to the patient. (This criterion is to be added to the initial approval criteria and to the renewal criteria)

The committee discussed Olumiant and recommended to the department by a unanimous vote that Olumiant remain on PA, with the addition of the following criterion: “Patient must be at least 18 years of age”

The committee discussed Siklos and recommended to the department by a unanimous vote that Siklos remain on PA, with the deletion of “for males” in the 5th bullet

The committee discussed Orilissa and recommended to the department by a unanimous vote that Orilissa remain on PA, with the following revisions:

1. Change the 7th bullet to the following: “Patient does not have a Z score of ≤ -1.5 at lumbar spine, femur (total hip) or back”
2. Addition of the following criterion: “Initial approval is for 6 months”

The committee discussed Macrilen and recommended to the department by a unanimous vote that Macrilen remain on PA

Adjournment

The meeting was adjourned at approximately 8:36 PM Central Time.